This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-21. Anything still debated is marked as such rather than presented as settled.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
James Windle notes that "prohibitions were enforced in Asian countries while the United States and Western Europe were routinely trading opium"; the "concept of prohibition being a distinctly American construct is, therefore, flawed". Collins concludes, "The United States was a key participant in the [International Drug Control System], albeit frequently an absent one, but hardly the sole force."
A metallocene is a compound typically consisting of two cyclopentadienyl anions (C5H−5, abbreviated Cp) bound to a metal center (M). They have the general formula (C5R5)2M]+ (R = H, alkyl typically). Closely related to the metallocenes are the metallocene derivatives, e.g. titanocene dichloride or vanadocene dichloride. Certain metallocenes and their derivatives exhibit catalytic properties, although metallocenes are rarely used industrially. Cationic group 4 metallocene derivatives related to [Cp2ZrCH3]+ catalyze olefin polymerization. Metallocenes are a subset of a broader class of compounds called sandwich compounds. In the structure shown at right, the two pentagons are the cyclopentadienyl anions with circles inside them indicating they are aromatically stabilized. Here they are shown in a staggered conformation.
=== Psychiatric disorders === Cyproheptadine was studied in one small trial as an adjunct in people with schizophrenia whose condition was stable and were on other medication; while attention and verbal fluency appeared to be improved, the study was too small to draw generalizations from. It has also been studied as an adjuvant in two other trials in people with schizophrenia, around fifty people overall, and did not appear to have an effect. Cyproheptadine has been studied for the treatment of post-traumatic stress disorder.
== Health concerns == The manipulation of the gut flora is complex and may cause bacteria-host interactions. Although probiotics, in general, are considered safe, there are concerns about their use in certain cases. Some people, such as those with compromised immune systems, short bowel syndrome, central venous catheters, heart valve disease and premature infants, may be at higher risk for adverse events. Rarely, consumption of probiotics may cause bacteremia, and sepsis, potentially fatal infections in children with lowered immune systems or who are already critically ill.
Supercritical drying is a method of removing solvent without surface tension effects. As a liquid dries, the surface tension drags on small structures within a solid, causing distortion and shrinkage. Under supercritical conditions there is no surface tension, and the supercritical fluid can be removed without distortion. Supercritical drying is used in the manufacturing process of aerogels and drying of delicate materials such as archaeological samples and biological samples for electron microscopy.
Sources: en.wikipedia.org
On 13 December 1904, Hungarian Sándor Just and Croatian Franjo Hanaman were granted a Hungarian patent (No. 34541) for a tungsten filament lamp that lasted longer and gave brighter light than the carbon filament. Tungsten filament lamps were first marketed by the Hungarian company Tungsram in 1904. This type is often called Tungsram-bulbs in many European countries. Filling a bulb with an inert gas such as argon or nitrogen slows the evaporation of the tungsten filament compared to operating it in a vacuum. This allows for greater temperatures and therefore greater efficacy with less reduction in filament life. In 1906, William D. Coolidge developed a method of making "ductile tungsten" from sintered tungsten which could be made into filaments while working for General Electric Company. By 1911 General Electric had begun selling incandescent light bulbs with ductile tungsten wire. In 1913, Irving Langmuir found that filling a lamp with inert gas (nitrogen at first, and later argon) instead of a vacuum resulted in twice the luminous efficacy and reduced bulb blackening. He patented his device on April 18, 1916.
The non-protein amino acid-accumulating clade, also known as the Canavanine-accumulating clade, is a clade of the flowering plant subfamily Faboideae (or Papilionoideae) that includes the majority of agriculturally-cultivated legumes. It is characterized by the accumulation of the non-proteinogenic amino acid canavanine in the seeds—a deterrent against herbivory. This phylogenetic trait was first recognized in the early 1980s. This clade is consistently resolved in molecular phylogenies. It contains many economically important genera, including Cicer, Glycine, Medicago, Phaseolus, Trifolium, Vicia, and Vigna.
=== National service === Heseltine had transferred his articles to a partner at a smaller firm of accountants located off Haymarket, feeling that this would allow him more chance of hands-on involvement in the affairs of the firms whose books he examined, rather than being a cog in a bigger machine. It took him three attempts and special coaching to pass his intermediate exams, and he had little immediate prospect of passing his accountancy finals. He also estimated that he was earning more from his property business than the partner to whom he was articled. With the expiry of his articles in January 1958 he could no longer avoid conscription into National Service. Heseltine later wrote that he admired the military, for his father had been a lieutenant-colonel in the Royal Engineers in the Second World War and active in the Territorial Army thereafter, but that he had felt that his business career was too important to be disrupted. He and his father had taken the precaution of arranging interviews to increase his chances of attaining an officer's commission in case he had to serve. He had been lucky not to be called up for the Korean War in the early 1950s or the Suez Crisis in 1956; and in the final years of National Service, already due for abolition by 1960, an effort was made to call up men who had so far managed to postpone service. Despite having almost reached maximum call-up age, recently reduced from thirty to twenty-six, Heseltine was conscripted into the Welsh Guards in January 1959.
== Symptoms and signs == In terms of the signs/symptoms of Fukuyama congenital muscular dystrophy it is characterized by a decrease in skeletal muscle tone as well as an impairment in brain and eye development. Initial symptoms of FCMD present in early infancy as decreased ability to feed. Marked differences in facial appearance occur due to decreased muscle tone. Further characteristics include:
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.